Jose Manuel Puerta
Overview
Explore the profile of Jose Manuel Puerta including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
5
Citations
67
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Hernandez-Boluda J, Pereira A, Pastor-Galan I, Alvarez-Larran A, Savchuk A, Puerta J, et al.
Blood Cancer J
. 2018 Dec;
8(10):91.
PMID: 30504932
Over half of chronic myeloid leukemia (CML) patients in deep molecular response do not lose the major molecular response (MMR) after stopping treatment with tyrosine kinase inhibitors (TKI). This strategy...
2.
Garcia-Gutierrez V, Milojkovic D, Hernandez-Boluda J, Claudiani S, Martin Mateos M, Casado-Montero L, et al.
Ann Hematol
. 2018 Nov;
98(2):321-330.
PMID: 30446802
Bosutinib is a second-generation tyrosine kinase inhibitor (2GTKI) approved at 400 mg once daily (QD) as first-line therapy in patients with chronic myeloid leukemia (CML) patients and at 500 mg...
3.
Rios-Tamayo R, Sainz J, Martinez-Lopez J, Puerta J, Chang D, Rodriguez T, et al.
Am J Hematol
. 2016 Apr;
91(7):700-4.
PMID: 27074204
Multiple myeloma is a heterogeneous disease with variable survival; this variability cannot be fully explained by the current systems of risk stratification. Early mortality remains a serious obstacle to further...
4.
Trends in survival of multiple myeloma: a thirty-year population-based study in a single institution
Rios-Tamayo R, Sanchez M, Puerta J, Sainz J, Chang D, Rodriguez T, et al.
Cancer Epidemiol
. 2015 Aug;
39(5):693-9.
PMID: 26277330
Background: Despite the progress made in recent years, multiple myeloma is still considered an incurable disease. Most survival data come from clinical trials. Little is known about the outcome in...
5.
Garcia-Gutierrez V, Puerta J, Maestro B, Casado Montero L, Muriel A, Molina Hurtado J, et al.
Am J Hematol
. 2014 Jul;
89(11):E206-11.
PMID: 25059397
In the latest recommendations for the management of chronic-phase chronic myeloid leukemia suboptimal responses have been reclassified as "warning responses." In contrast to previous recommendations current guidance advises close monitoring...